478 related articles for article (PubMed ID: 21867843)
1. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
Maisel A; Mueller C; Nowak RM; Peacock WF; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng LL; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Hartmann O; Morgenthaler NG; Anker SD
J Am Coll Cardiol; 2011 Aug; 58(10):1057-67. PubMed ID: 21867843
[TBL] [Abstract][Full Text] [Related]
2. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
Maisel A; Mueller C; Nowak R; Peacock WF; Landsberg JW; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD
J Am Coll Cardiol; 2010 May; 55(19):2062-76. PubMed ID: 20447528
[TBL] [Abstract][Full Text] [Related]
3. Short-term mortality risk in emergency department acute heart failure.
Peacock WF; Nowak R; Christenson R; DiSomma S; Neath SX; Hartmann O; Mueller C; Ponikowski P; Möckel M; Hogan C; Wu AH; Richards M; Filippatos GS; Anand I; Ng LL; Daniels LB; Morgenthaler N; Anker SD; Maisel AS
Acad Emerg Med; 2011 Sep; 18(9):947-58. PubMed ID: 21906204
[TBL] [Abstract][Full Text] [Related]
4. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
[TBL] [Abstract][Full Text] [Related]
6. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
[TBL] [Abstract][Full Text] [Related]
7. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.
Xue Y; Taub P; Iqbal N; Fard A; Clopton P; Maisel A
Eur J Heart Fail; 2013 Dec; 15(12):1343-9. PubMed ID: 23887059
[TBL] [Abstract][Full Text] [Related]
8. Stress markers predict mortality in patients with nonspecific complaints presenting to the emergency department and may be a useful risk stratification tool to support disposition planning.
Nickel CH; Messmer AS; Geigy N; Misch F; Mueller B; Dusemund F; Hertel S; Hartmann O; Giersdorf S; Bingisser R
Acad Emerg Med; 2013 Jul; 20(7):670-9. PubMed ID: 23859580
[TBL] [Abstract][Full Text] [Related]
9. The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea.
Wu AH; Tabas J; Stein J; Potocki M; Mueller C; McCord J; Richards M; Hartmann O; Nowak R; Peacock WF; Ponikowski P; Moeckel M; Hogan C; Filippatos GS; Di Somma S; Anand I; Ng L; Neath SX; Christenson R; Morgenthaler NG; Anker SD; Maisel AS
Biomarkers; 2012 Sep; 17(6):490-7. PubMed ID: 22616939
[TBL] [Abstract][Full Text] [Related]
10. Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial.
Möckel M; Searle J; Hartmann O; Anker SD; Peacock WF; Wu AH; Maisel A; ; Slagman A; Vollert JO; Papassotiriou J; Anand I; Christenson R; Daniels LB; Filippatos GS; Hogan C; Morgenthaler N; Mueller C; Neath SX; Ng L; Nowak R; Richards M; Di Somma S; Ponikowski P
Emerg Med J; 2013 Aug; 30(8):633-7. PubMed ID: 22962091
[TBL] [Abstract][Full Text] [Related]
11. MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.
Heining L; Giesa C; Ewig S
Lung; 2016 Apr; 194(2):185-91. PubMed ID: 26748496
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
[TBL] [Abstract][Full Text] [Related]
13. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study.
Christ-Crain M; Morgenthaler NG; Struck J; Harbarth S; Bergmann A; Müller B
Crit Care; 2005; 9(6):R816-24. PubMed ID: 16356231
[TBL] [Abstract][Full Text] [Related]
14. Time-dependent Cox regression: serial measurement of the cardiovascular biomarker proadrenomedullin improves survival prediction in patients with lower respiratory tract infection.
Hartmann O; Schuetz P; Albrich WC; Anker SD; Mueller B; Schmidt T
Int J Cardiol; 2012 Nov; 161(3):166-73. PubMed ID: 23017815
[TBL] [Abstract][Full Text] [Related]
15. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
Walter T; Brueckmann M; Lang S; Sauer T; Fiedler E; Papassotiriou J; Behnes M; Elmas E; Borggrefe M; Bertsch T
Clin Lab; 2010; 56(7-8):303-9. PubMed ID: 20857894
[TBL] [Abstract][Full Text] [Related]
16. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.
Cinar O; Cevik E; Acar A; Kaya C; Ardic S; Comert B; Yokusoglu M; Bilgi C; Meisner M; Madsen T
Am J Emerg Med; 2012 Nov; 30(9):1915-20. PubMed ID: 22742951
[TBL] [Abstract][Full Text] [Related]
18. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain.
Tzikas S; Keller T; Ojeda FM; Zeller T; Wild PS; Lubos E; Kunde J; Baldus S; Bickel C; Lackner KJ; Münzel TF; Blankenberg S
Heart; 2013 Mar; 99(6):388-95. PubMed ID: 23213173
[TBL] [Abstract][Full Text] [Related]
19. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients.
Haaf P; Twerenbold R; Reichlin T; Faoro J; Reiter M; Meune C; Steuer S; Bassetti S; Ziller R; Balmelli C; Campodarve I; Zellweger C; Kilchenmann A; Irfan A; Papassotiriou J; Drexler B; Mueller C
Int J Cardiol; 2013 Sep; 168(2):1048-55. PubMed ID: 23199555
[TBL] [Abstract][Full Text] [Related]
20. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
